These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20590025)

  • 21. Insulin analog lispro decreases insulin resistance and improves glycemic control in an obese patient with insulin-requiring type 2 diabetes.
    Darmon P; Curtillet C; Boullu S; Laugier A; Dutour A; Oliver C
    Diabetes Care; 1998 Sep; 21(9):1575. PubMed ID: 9727917
    [No Abstract]   [Full Text] [Related]  

  • 22. Type 2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism?
    Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
    Diabet Med; 2011 Mar; 28(3):276-86. PubMed ID: 21309835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin detemir--a new basal insulin analog.
    Goldman-Levine JD; Lee KW
    Ann Pharmacother; 2005 Mar; 39(3):502-7. PubMed ID: 15657117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analog insulin preparations in patients with type 2 diabetes. Better rapid and brief than sluggish and long].
    MMW Fortschr Med; 2005 Nov; 147(46):60. PubMed ID: 16358638
    [No Abstract]   [Full Text] [Related]  

  • 26. Inhaled insulin (exubera).
    Med Lett Drugs Ther; 2006 Jul; 48(1239):57-8. PubMed ID: 16841019
    [No Abstract]   [Full Text] [Related]  

  • 27. Insulin detemir: a new basal insulin analogue.
    Soran H; Younis N
    Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin lispro: new preparation. Faster acting.
    Prescrire Int; 1998 Jun; 7(35):67-8. PubMed ID: 10342918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of glycemia in patients with diabetes mellitus and CKD.
    Lubowsky ND; Siegel R; Pittas AG
    Am J Kidney Dis; 2007 Nov; 50(5):865-79. PubMed ID: 17954300
    [No Abstract]   [Full Text] [Related]  

  • 30. The prognosis and management of diabetic nephropathy.
    Watkins PJ; Parsons V; Bewick M
    Clin Nephrol; 1977 Jun; 7(6):243-9. PubMed ID: 872462
    [No Abstract]   [Full Text] [Related]  

  • 31. Inhaled human insulin ((insulin human [rDNA origin]) Inhalation Powder) in diabetes mellitus.
    Mathieu C
    Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):779-91. PubMed ID: 17014394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin glargine (Lantus) and cancer risk.
    Med Lett Drugs Ther; 2009 Aug; 51(1319):67-8. PubMed ID: 19696708
    [No Abstract]   [Full Text] [Related]  

  • 33. Insulin in the early management of diabetic complications.
    Miles JM
    J Assoc Physicians India; 2003 May; 51():501-5. PubMed ID: 12974435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Putting insulin glargine and malignancies into perspective.
    Ehninger G; Schmidt AH
    Oncologist; 2009 Dec; 14(12):1169-74. PubMed ID: 20007644
    [No Abstract]   [Full Text] [Related]  

  • 35. [Non-alcoholic fatty liver disease in dyslipidemia and insulin resistance: similarities and differences; differential approach to therapy].
    Lazebnik LB; Zvenigorodskaia LA; Egorova EG; Mel'nikova NV; Khomeriki SG
    Eksp Klin Gastroenterol; 2009; (8):4-11. PubMed ID: 20469672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
    Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
    Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2008 resource guide. Insulin. Along with human insulin analogs, recombinant DNA human insulins are the most widely used insulins in this country. Through genetic engineering, bacteria or yeast are transformed into little "factories" that produce synthetic human insulin.
    Diabetes Forecast; 2008 Jan; 61(1):RG11-4. PubMed ID: 18290288
    [No Abstract]   [Full Text] [Related]  

  • 38. [CME: Antidiabetics in renal failure and kidney transplantation].
    Seer C; Lehmann R
    Praxis (Bern 1994); 2016 Jan; 105(2):69-74; quiz 75-6. PubMed ID: 26787327
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacokinetics of insulin and oral antidiabetic drugs in renal insufficiency.
    Hasselblatt A
    Contrib Nephrol; 1989; 73():139-45; discussion 146. PubMed ID: 2689089
    [No Abstract]   [Full Text] [Related]  

  • 40. [Which form of therapy (insulin therapy or oral antidiabetics) is best for a patient with newly diagnosed type 2 diabetes mellitus?].
    Lehmann R
    Praxis (Bern 1994); 1998 Oct; 87(41):1368-9. PubMed ID: 9828668
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.